Everest Clinical Research Acquires Firma's Biometrics Unit to Expand Global Data Science Capabilities

The Quick Take

• Everest Clinical Research, backed by Arlington Capital Partners, acquired the Biometrics and Data Services unit of Firma Clinical Research
• The acquisition expands Everest's global biometrics expertise and clinical data science capabilities as a full-service CRO
• Everest gains specialized capacity in biostatistics, data management, and clinical programming to compete for larger global trials

Everest Clinical Research's acquisition of Firma Clinical Research's Biometrics and Data Services business unit is a targeted capability purchase within the contract research organization sector, where data science and biostatistics depth increasingly determines competitive positioning on large Phase II-III clinical trials. Arlington Capital Partners, the Washington D.C.-area private equity owner of Everest, is following a build-through-acquisition playbook common in CRO consolidation, where specialized data capabilities command premium valuations from pharmaceutical and biotech sponsors.

The CRO industry has been undergoing consolidation as global pharma and biotech companies seek fewer, deeper partnerships with full-service organizations rather than managing multiple specialized vendors. Firm DS brings biostatistics, data management, and clinical programming capabilities that allow Everest to compete directly with larger integrated CROs such as ICON, Syneos, and PRA Health Sciences on contracts that require end-to-end data science support. The deal strengthens Everest's negotiating position with mid-cap biotech sponsors in North America who prioritize data quality credentials.

The watch point for this deal is post-close integration — particularly whether Firma DS's existing client relationships and technical staff are retained. CRO acquisitions frequently see client attrition if key personnel depart during integration. Revenue synergies will materialize fastest if Everest can cross-sell biometrics capabilities to its existing clinical operations client base. The macro variable is pharma R&D spending levels — a contraction in biotech funding could reduce outsourced clinical trial volumes and slow the return on this acquisition.

Synthesized from 1 source.